228123-15-7|AH-1058 HCl|Piperidine, 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-((2E)-3-(3-methoxy-2-nitrophenyl)-2-propen-1-yl)-, hydrochloride (11)|-范德生物科技公司

AH-1058 HCl

NMR下载 COA and HPLC MSDS下载
names：
Piperidine, 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-((2E)-3-(3-methoxy-2-nitrophenyl)-2-propen-1-yl)-, hydrochloride (11)
CAS号：
228123-15-7
MDL Number：
MF(分子式)： C30H29ClN2O3 MW(分子量)： 501.02
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	AH-1058 HCl
英文别名	AH-1058 HCl; AH 1058 HCl; AH1058 HCl
CAS号	228123-15-7
Inchi	InChI=1S/C30H28N2O3.ClH/c1-35-28-14-6-10-25(30(28)32(33)34)11-7-19-31-20-17-24(18-21-31)29-26-12-4-2-8-22(26)15-16-23-9-3-5-13-27(23)29;/h2-16H,17-21H2,1H3;1H/b11-7+;
InchiKey	HUGNVHKJRQLOAZ-RVDQCCQOSA-N
分子式 Formula	C30H29ClN2O3
分子量 Molecular Weight	501.02
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	AH-1058 HCl(CAS:228123-15-7):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	AH-1058 HCl is a lipophilic antiarrhythmic calcium channel blocker. It is derived from cyproheptadine, a compound with known antiserotonic, antihistaminic and calcium channel blocking properties.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Dohmoto H, Takahara A, Uneyama H, Yoshimoto R. Cardiac Ca(2+) channel-blocking effects of the cyproheptadine derivative AH-1058 in isolated guinea pig cardiomyocytes. J Pharmacol Sci. 2003 Feb;91(2):163-6. PubMed PMID: 12686762.

[2]Takahara A, Sugiyama A, Yoshimoto R, Hashimoto K. AH-1058: a novel cardioselective Ca2+ channel blocker. Cardiovasc Drug Rev. 2001 Winter;19(4):279-96. Review. PubMed PMID: 11830748.

[3] Takahara A, Hirasawa A, Dohmoto H, Shoji M, Yoshimoto R, Sugiyama A, Hashimoto K. In vivo antiarrhythmic profile of AP-792 assessed in different canine arrhythmia models. Jpn J Pharmacol. 2001 Sep;87(1):21-6. PubMed PMID: 11676194.

[4] Takahara A, Dohmoto H, Yoshimoto R, Sugiyama A, Hashimoto K. Utilization of telemetry system to assess the cardiovascular profile of AH-1058, a new cardioselective Ca2+ channel blocker, in conscious dogs. Jpn J Pharmacol. 2001 Mar;85(3):331-4. PubMed PMID: 11325028.

[5] Takahara A, Dohmoto H, Yoshimoto R, Sugiyama A, Hashimoto K. Cardiovascular action of a cardioselective Ca(2+)channel blocker AH-1058 in conscious dogs assessed by telemetry. Eur J Pharmacol. 2001 Feb 9;413(1):101-8. PubMed PMID: 11173068.

6: Takahara A, Sugiyama A, Dohmoto H, Yoshimoto R, Hashimoto K. Electrophysiological and cardiohemodynamic effects of AH-1058, a new type calcium channel blocker, assessed by the in vivo canine model. Jpn J Pharmacol. 2000 Jun;83(2):107-12. PubMed PMID: 10928322.7: Takahara A, Sugiyama A, Dohmoto H, Yoshimoto R, Hashimoto K. Antiarrhythmic and cardiohemodynamic effects of a novel Ca(2+) channel blocker, AH-1058, assessed in canine arrhythmia models. Eur J Pharmacol. 2000 Jun 9;398(1):107-12. PubMed PMID: 10856454.8: Takahara A, Sugiyama A, Dohmoto H, Yoshimoto R, Hashimoto K. Comparison of cardiovascular effects of a new calcium channel blocker AH-1058 with those of verapamil assessed in blood-perfused canine heart preparations. J Cardiovasc Pharmacol. 2000 May;35(5):741-8. PubMed PMID: 10813376.9: Tanaka H, Ichikawa T, Matsui S, Okazaki K, Masumiya H, Kawanishi T, Shigenobu K. Calcium channel antagonistic effects of AH-1058, a novel antiarrhythmic drug, on guinea-pig myocardium. Res Commun Mol Pathol Pharmacol. 1999;104(1):13-21. PubMed PMID: 10604274.10: Takahara A, Uneyama H, Sasaki N, Ueda H, Dohmoto H, Shoji M, Hara Y, Nakaya H, Yoshimoto R. Effects of AH-1058, a new antiarrhythmic drug, on experimental arrhythmias and cardiac membrane currents. J Cardiovasc Pharmacol. 1999 Apr;33(4):625-32. PubMed PMID: 10218734.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开